It's a good thesis thinking about fiscal growth more stimulus and covid vaccine availability. Not a direct relation fiscally as other opportunities and probably a bit of pull back...another one for the watch list and company analysis.
Thursday's OPEC+ meeting became a market-mover event, as members announced that production cuts would be extended in April. This caught the market completely off guard, as OPEC+ was widely expected to raise output by 500,000 barrels per month. Instead, OPEC+ has opted to hold back some 9.2 million barrels from the market each day, until at least the beginning of...
Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2...
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish...
Again... hypothetical testing by pushing the technical indicators and it appears that the UK would see a slight resurgence of COVID-19 cases. May need about eight weeks plus minus two weeks to see something...
Gold showing signs of a more dominant progress north, to really understand where I am going with this, you need to view my previous charts linked below. I at first seen a possible break north in the early new year, this started as planned, alas the new variant came and further decline progressed, I outlined this possible drop in my previous charts, but did not...
Chart of Singapore’s COVID-19 cases, since October predicted a rise in case numbers, which played out with a small spike in December. Posted in November about this idea. From February onwards, the risk appears to decelerate and lower. Slight indication of next smaller spike wave may be appearing... check in again in two weeks to see.
Why $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in...
With the overnight share issue at a premium of 7.65 (up from 5.25) and pre-market on 8/2/21 at 8.9 the hopium on the higher time frames may not seem so far fetched. Ocugen may be the dark horse to win the Covid-19 vaccine race.
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis. finance.yahoo.com
OCGN: What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken –...
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from...
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of...
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine...
A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed? over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race. Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and...
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase...